VIDEO: Deepak L. Bhatt, MD, MPH, highlights new data on semaglutide, tirzepatide at AHA
Click Here to Manage Email Alerts
PHILADELPHIA — In this Healio exclusive, Deepak L. Bhatt, MD, MPH, provides his perspective on research presented at the American Heart Association Scientific Sessions.
Bhatt discusses the SELECT trial, which is the first to show a reduction in hard cardiovascular outcomes for an obesity treatment.
“From a bottom-line perspective, I would categorize this trial as a home run,” Bhatt said. “This extends our knowledge of semaglutide 2.4 mg (Wegovy, Novo Nordisk) and shows benefit not just in those with diabetes but even in those without diabetes who have overweight or obesity plus cardiovascular disease.”
Bhatt also provides highlights from a post hoc analysis of the SURPASS-4 trial that found tirzepatide (Mounjaro, Eli Lilly) reduced high-sensitivity C-reactive protein in patients with type 2 diabetes and high cardiovascular risk.
“Will this reduction in inflammation translate into reduction of cardiovascular events?” Bhatt said. A cardiovascular outcomes trial is ongoing and will hopefully provide an answer in the future.
Watch the video for take-home messages from Bhatt, who is director of Mount Sinai Heart, the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai and a member of the Healio | Cardiology Today Editorial Board.
Collapse
Read more about
Click Here to Manage Email Alerts